regorafenib
bayer
[]
integrate phase 3 trial of rego vs placebo (agoc) noted os for primary endpoint in refractory ge cancer. #cancer #cancerresearch #clinicaltrials #ascogi23 #gi23 #ascogi
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations